Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated Phase 2 IOV-LUN-202 results for lifileucel in previously treated metastatic non-squamous NSCLC.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated Phase 2 IOV-LUN-202 results for lifileucel in previously treated metastatic non-squamous NSCLC
- Cohorts 1 and 2 data may inform lifileucel efficacy and safety assessment in lung cancer
- Biomarker-enriched strategy targets improved patient selection and potential clinical differentiation
- Full results and disclosures in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Lifileucel ORR 24.6% in 69 previously treated non-squamous mNSCLC patients, consistent with prior 25.6% result
- KRAS wild-type ORR 43.3% versus 11.4% for KRAS-mutant disease, with both complete responses in KRAS wild-type tumors
- Biomarker-enriched subgroup ORR 59.1% (13/22), concentrating 76.5% of responses in 31.9% of patients
- POSITILITY prospective biomarker-enriched cohort begins enrollment November 2026, supporting potential registrational pathway
- Cohorts 1 and 2 nearing completion, with approximately 80 patients expected and sBLA planned for 2027 subject to FDA feedback
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.